Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2000-09-01
2004-11-30
Eyler, Yvonne (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S350000, C530S300000, C530S387100, C530S388100, C435S007100, C435S007200, C435S007210, C435S006120, C424S009100, C424S009200, C204S450000, C536S023100, C536S023400, C536S023500, C536S024330, C536S024310
Reexamination Certificate
active
06824995
ABSTRACT:
ACKNOWLEDGMENT OF FEDERAL RESEARCH SUPPORT
Not applicable.
BACKGROUND OF THE INVENTION
Prostate cancer accounts for about 1 in 10 cancer cases in the United States, and it is the most often diagnosed cancer in males [Henderson et al. (1991)
Science
254,1131-1138]. While in many affected patients, the tumors are slow-growing and nonmetastatic, in others the malignant prostate tumors are aggressive and metastasize. When prostate cancer metastasizes, the prognosis for the patient is poor, especially without treatment.
To date, the most frequently used test for prostate cancer is the serum level of prostate specific antigen (PSA) and the radionuclide bone scan for detecting prostate cancer metastases before definitive therapy is initiated. However, the elevated level of PSA in serum is not predictive of the pathologic stage of the prostate cancer or the presence of metastatic disease. PSA, a serine protease, is not exclusively expressed in the epithelial cells of metastatic prostate cancer, but it is also expressed in normal epithelial cells, primary tumors and benign prostate hyperplasia.
The altered expression of cell-adhesion molecules has been correlated with metastasis of many cancers. Low or no expression of E-cadherin, a cell-adhesion molecule, has been found in high-grade prostate carcinoma, and this indicates a poor prognosis for those prostate cancer patients. However, the absence of an antigen is not very useful as a diagnostic marker for cancer metastasis.
MUC18 is a glycoprotein of about 113 kDa which serves as a cell adhesion molecule on the surface of melanoma cells, and it has been correlated with the ability of melanomas to metastasize [See, e.g., Lehmann et al. (1989)
Proc. Nat. Acad. Sci. USA
86, 9891-9895; Luca et al. (1993)
Melanoma Res
. 3, 3541; Johnson et al. (1996)
Curr. Top. Microbiol. Immunol
. 213, 95-105; Xie et al. (1997)
Cancer Res
. 57, 2295-2303; Tang and Honn (1994-1995)
Invasion Metas
. 14, 109-122; Rummel et al. (1996)
Cancer Res
. 56, 2218-2223]. MUC18 is also known as MCAM and CD146. MUC18 carries a carbohydrate modification known as HNK-1 or CD57 [Shih et al. (1994)
Cancer Res
. 54, 2514-2520]. Besides being associated with melanoma cells' ability to metastasize, MUC18 is also associated with normal vascular tissue, and on the smooth muscle of venules, and it expresses sporadically on capillary epithelium [Johnson, J. (1994-1995)
Invasion Metas
. 14, 123-130].
There is a longfelt need in the art for an improved diagnostic test for metastatic prostate cancer so that appropriate therapy can be initiated as soon as possible and so that the number of false positive results can be minimized.
SUMMARY OF THE INVENTION
The present invention provides an improved diagnostic test for prostate cancer which has a relatively high potential for metastasis or which has metastasized. This allows the physician to choose appropriate surgical, chemotherapeutic or radiation treatment regimens. This improved assay is based on the correlation of high levels of expression of the MUC18 coding sequence as measured by MUC18 mRNA or MUC18 protein. This expression can be detected at the transcriptional level, where mRNA levels are monitored, or detection of the MUC18 gene product at the translation level can be determnined, for example, through the use of an immunoassay for the MUC18 protein. The source of the material for these tests is prostate biopsy tumor tissue (e.g., from a needle biopsy) from a patient needing a determination of the metastatic potential of a prostate tumor or from cells from a prostate tumor.
Relative levels of transcriptional expression (mRNA) of the MUC18 coding sequence can be determined by Northern hybridization analysis or by quantitative reverse transcription polymerase chain reaction (RT-PCR) in normal and neoplastic prostate tissue samples and in biopsy material.
Translational expression of MUC18 can be determined by any of a number of adaptations of an immunoassay using antibody specific for the MUC18 cell surface antigen. The relative level of MUC18 can be determined by standard immunoassays using a MUC18-specific antibody preparation and a detection system suitable for the assay. Immunoassays can include, but are not limited to, immunofluorescence assays, radioimmunoassay, enzyme-linked immunosorbent assays, and Western (immuno) blot assays. In the context of the present invention, relative amounts of the MUC18 protein are determined in tissue samples (e.g., biopsy material).
It is a further object of the present invention to provide an antibody which inhibits prostate cancer metastasis. In particular, antibody specific to MUC18 prevents metastasis of prostate cancer cells.
Additional objects include vectors directing the expression of an immunogenic fragment of human MC18and the corresponding recombinantly expressed protein. As specifically exemplified, an immunogenic fragment of human MUC18 is encoded by the PvuII to XhoI fragment within the sequence given in Tables 1A-1B.
REFERENCES:
patent: 5807978 (1998-09-01), Kokolus et al.
patent: 6057105 (2000-05-01), Hoon et al.
patent: 6184043 (2001-02-01), Fodstad et al.
patent: 9634117 (1996-10-01), None
patent: 9728193 (1997-08-01), None
Rubenstein, M, et al, 1989, Application of immunohistologic staining to develop a malignant index to aid in distinguishing benign from malignant prostatic tissue, Prostate, vol. 14, pp. 383-388.*
Shih, I-M, et al, 1994; Isolation and functional characterization of the A32 melanoma-associated antigen, Cancer Research, vol. 54, pp. 2514-2520.*
Liu, XH, et al, 1993, The prognostic value of the HNK-1 (Leu-7) antigen in prostatic cancer—an immunohistochemical study, Hinyokika Kiyo Acta Urologica Japonica, vol. 39, pp. 439-444.*
Filshie, RJ, et al, 1998, Leukemia, MUC18, a member of the immunoglobulin superfamily, is expressed on bone marrow fibroblasts and a subset of hematological malignanciesvol. 12, pp. 414-421.*
Shih, IM, et al, 1996, Diagnostic and biological implications of mel-CAM expression in mesenchymal neoplasms, Clinical Cancer Research, vol. 2, pp. 569-575.*
Kraus, A, et al, 1997, Analysis of the expression of intracellular adhesion molecule-1 and MUC18 on benign and malignant melanocytic lesions using monoclonal antibodies directed against distinct epitopes . . . , Melanoma Research, vol. 7, pp. s75-81.*
Swiss Protein Database, Accession No. P43121, MU18_Human Standard; PRT; 646 AA (Search Report US-09-653-961-2.rsp, result No. 1).*
Weninger, W, et al, 2000, Keratinocytes express the CD146 (Muc18/S-Endo) antigen in tissue culture and during inflammatory skin diseases, Journal of Investigative Dermatology, vol. 115, pp. 219-224.*
Hsu, M-Y, et al, 2000, E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors, American Journal of Pathology, vol. 156, pp. 1515-1525.*
Wu, G-J, et al, 2001, Prostate 48: 305-315.*
Wu GJ, et al. Gene. Nov. 14, 2001; 279 (1): 17-31.*
Brannen et al. (1975) “Specificity of Cell Membrane Antigens in Prostatic Cancer”Cancer Chemotherapy Reportsvol. 59, No. 1:127-138.
Brannen et al. (unknown) “Specificity of Cell Membrane Antigens in Prostate Cancer”National Cancer Institute Monograph49:251-253.
Catalona et al. (1978) “Carcinoma of the Prostate: A Review”The Journal of Urology119:1-8.
Judith P. Johnson (1994) “Identification of Molecules Associated with the Development of Metastasis in Human Malignant Melanoma”Invasion Metastasis14:123-130.
Johnson et al. (1996) “MUC18: A Cell Adhesion Molecule with a Potential Role in Tumor Growth and Tumor Cell Dissemination”Current Topics in Microbiology and Immunology213:95-105.
Lehmann et al. (1989) “MUC18, a Marker of Tumor Progression in Human Melanoma, Shows Sequence Similarity to the Neural Cell Adhesion Molecules of the Immunoglobulin Superfamily”Proc. Natl. Acad. Sci. USA86:9891-9895.
Luca, et al. (1993) “Direct Correlation Between MUC18 Expression and Metastatic Potential of Human Melanoma Cells”Melanoma Research3:35-41.
Pantel
Emory University
Eyler Yvonne
Greenlee Winner and Sullivan P.C.
Rawlings Stephen L.
LandOfFree
Diagnostic for metastatic prostate cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic for metastatic prostate cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic for metastatic prostate cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3294149